Koyama S, et al. - A retrospective study was conducted to determine the efficacy and safety of lenvatinib in anaplastic thyroid cancer (ATC). Outcomes suggested lenvatinib to be an effective treatment that could improve the prognosis of unresectable ATC. Hypothyroidism was a common treatment-related adverse effect. Many treatment-related adverse effects were encountered, most of which were manageable by dose modification and medical therapy.